https://phrma.org/home https://phrma.org/about https://phrma.org/about/leadership https://phrma.org/about/ethics-codes-guidelines https://phrma.org/about/john-corea https://phrma.org/about/lauren-olcott https://phrma.org/about/lindsey-seidlitz https://phrma.org/about/megan-van-etten https://phrma.org/about/michelle-nyman https://phrma.org/about/ali-lapidus https://phrma.org/about/drew-voytal https://phrma.org/about/abigail-lore https://phrma.org/about/amber-lyons https://phrma.org/about/amey-sutkowski https://phrma.org/about/anita-roach-ms https://phrma.org/about/anne-mcdonald-pritchett-phd https://phrma.org/about/ashley-czin https://phrma.org/about/ashley-flint https://phrma.org/about/bill-chin-m-d https://phrma.org/about/brian-newell https://phrma.org/about/brooke-ringel https://phrma.org/about/caitlin-carroll https://phrma.org/about/camille-jackson https://phrma.org/about/chris-moore https://phrma.org/about/christian-clymer https://phrma.org/about/eileen-cannon https://phrma.org/about/emma-van-hook https://phrma.org/about/gabriela-lavezzari https://phrma.org/about/hannah-mooney-mack https://phrma.org/about/holly-campbell https://phrma.org/about/jeff-francer https://phrma.org/about/jennifer-bryant https://phrma.org/about/john-castellani https://phrma.org/about/john-tunnell https://phrma.org/about/mark-reisenauer-and-stephen-j-ubl https://phrma.org/about/nicole-longo https://phrma.org/about/tiffany-haverly https://phrma.org/about/saumil-pandya-and-emily-donaldson https://phrma.org/about/samantha-hinkle https://phrma.org/about/ryan-garofalo https://phrma.org/about/richard-moscicki-m-d https://phrma.org/about/myisha-gatson https://phrma.org/about/katie-verb https://phrma.org/about/katie-koziara https://phrma.org/about/juliet-johnson https://phrma.org/about/joseph-havey https://phrma.org/about/joe-vandigo https://phrma.org/about/jasmine-gossett https://phrma.org/about/jackie-mcrae https://phrma.org/about/ieva-m-augstums https://phrma.org/about/guest-contributor https://phrma.org/about/gretta-stone https://phrma.org/about/giovanni-caforio-m-d https://phrma.org/about/ernest-kawka-and-douglas-petersen https://phrma.org/about/emily-donaldson https://phrma.org/about/emilie-signora https://phrma.org/about/dr-steven-thomas https://phrma.org/about/dr-freda-lewis-hall https://phrma.org/about/debra-deshong https://phrma.org/about/allyson-funk https://phrma.org/about/alex-schriver https://phrma.org/about/carolyn-ha https://phrma.org/about/jay-taylor https://phrma.org/about/rebecca-marklund https://phrma.org/about/scott-laganga https://phrma.org/about/sharon-lamberton https://phrma.org/about/matthew-norawong https://phrma.org/about/mark-keida https://phrma.org/about/nick-mcgee https://phrma.org/about/sarah-k-martin https://phrma.org/about/kristin-williams https://phrma.org/about/mike-ybarra https://phrma.org/about/kevin-haninger https://phrma.org/about/douglas-petersen https://phrma.org/about/andrew-powaleny https://phrma.org/about/rebecca-nebel-phd https://phrma.org/about/sarah-ryan https://phrma.org/about/molly-jenkins https://phrma.org/about/ernest-kawka https://phrma.org/about/robert-zirkelbach https://phrma.org/about/elizabeth-carpenter https://phrma.org/about/rachel-weissman https://phrma.org/about/brian-picone https://phrma.org/about/courtney-christian https://phrma.org/about/cynthia-hicks https://phrma.org/about/richard-kane https://phrma.org/about/samantha-dougherty https://phrma.org/about/stephen-j-ubl https://phrma.org/about/john-corea1 https://phrma.org/about/jonathan-kimball https://phrma.org/about/josephine-martin https://phrma.org/about/kelsey-lang https://phrma.org/about/lauren-dipaola https://phrma.org/about/mark-grayson https://phrma.org/about/michelle-drozd https://phrma.org/about/mit-spears https://phrma.org/about/mollymae-metheny https://phrma.org/about/olivia-shopshear https://phrma.org/about/pete-martinez https://phrma.org/about/priscilla-vanderveer https://phrma.org/about/rebecca-davison https://phrma.org/about/rick-smith https://phrma.org/about/sarah-spurgeon https://phrma.org/about/sascha-haverfield https://phrma.org/about/setareh-samii https://phrma.org/about/stephanie-fischer https://phrma.org/about/stephen-j-ubl-and-giovanni-caforio-m-d https://phrma.org/about/tina-stow https://phrma.org/about/emily-ortman https://phrma.org/about/brianna-allen https://phrma.org/about/elise-shutzer https://phrma.org/about/fabian-lucero-and-nielah-tucker https://phrma.org/about/eliza-maciag https://phrma.org/about/mark-allen https://phrma.org/about/alexander-hardy https://phrma.org/about/miguel-fernandez-alcalde https://phrma.org/about/jean-michel-boers https://phrma.org/about/tracey-merchant https://phrma.org/about/lucy-vereshchagina-phd https://phrma.org/about/james-c-stansel https://phrma.org/about/renuka-iyer https://phrma.org/about/caroline-dunne https://phrma.org/about/ken-keller https://phrma.org/about/douglas-j-langa https://phrma.org/about/david-loew https://phrma.org/about/vasant-vas-narasimhan https://phrma.org/about/richard-f-pops https://phrma.org/about/tarek-rabah https://phrma.org/about/david-ricks https://phrma.org/about/chris-round https://phrma.org/about/jennifer-taubert https://phrma.org/about/jean-christophe-tellier https://phrma.org/about/chris-viehbacher https://phrma.org/about/emma-walmsley https://phrma.org/about/tatsuyuki-yasuno https://phrma.org/about/michael-petroutsas https://phrma.org/about/kyle-gano-ph-d https://phrma.org/about/ashley-magargee https://phrma.org/about/pascal-soriot https://phrma.org/about/tsutomu-nakagawa https://phrma.org/about/steve-schaefer https://phrma.org/about/elcin-barker-ergun https://phrma.org/about/thomas-gibbs https://phrma.org/about/barry-greene https://phrma.org/about/karyn-schwartz https://phrma.org/about/lauren-neves https://phrma.org/about/rachel-licata https://phrma.org/about/randy-burkholder https://phrma.org/about/ken-e https://phrma.org/about/daniel-o-day https://phrma.org/about/albert-bourla https://phrma.org/about/chris-boerner https://phrma.org/about/robert-a-bradway https://phrma.org/about/robert-m-davis https://phrma.org/about/stami-turk https://phrma.org/about/reid-porter https://phrma.org/about/tim-mcclung https://phrma.org/about/yolanda-hutchins https://phrma.org/about/anjam-aziz https://phrma.org/about/brad-bailey https://phrma.org/about/mike-doustdar https://phrma.org/about/hannah-loiacono https://phrma.org/about/chanse-jones https://phrma.org/about/sebastian-guth https://phrma.org/about/jocelyn-ulrich https://phrma.org/about/belen-garijo https://phrma.org/about/julie-kim https://phrma.org/about/gabby-migliara https://phrma.org/about/liz-mahar https://phrma.org/about/kristen-booze https://phrma.org/about/will-may https://phrma.org/about/tom-wilbur https://phrma.org/about/larry-kerr https://phrma.org/about/jim-stansel https://phrma.org/about/kate-sikora https://phrma.org/about/david-korn https://phrma.org/about/lori-reilly https://phrma.org/biologics-biosimilars https://phrma.org/blog https://phrma.org/blog-alerts https://phrma.org/contact-us https://phrma.org/drug-shortages https://phrma.org/international https://phrma.org/pipeline-collaborations https://phrma.org/policy-issues https://phrma.org/policy-issues/340b https://phrma.org/policy-issues/research-development https://phrma.org/policy-issues/research-development/clinical-trials https://phrma.org/policy-issues/research-development/biopharmaceutical-manufacturing https://phrma.org/policy-issues/research-development/economic-impact https://phrma.org/policy-issues/research-development/pdufa https://phrma.org/policy-issues/innovative-medicines https://phrma.org/policy-issues/future-of-medicine https://phrma.org/policy-issues/future-of-medicine/cancer https://phrma.org/policy-issues/future-of-medicine/digital-health https://phrma.org/policy-issues/future-of-medicine/amr https://phrma.org/policy-issues/future-of-medicine/cell-gene-therapies https://phrma.org/policy-issues/future-of-medicine/mental-health https://phrma.org/policy-issues/future-of-medicine/therapies https://phrma.org/policy-issues/future-of-medicine/pediatrics https://phrma.org/policy-issues/future-of-medicine/vaccines https://phrma.org/policy-issues/future-of-medicine/rare-diseases https://phrma.org/policy-issues/intellectual-property https://phrma.org/policy-issues/government-price-setting https://phrma.org/policy-issues/government-price-setting/inflation-reduction-act https://phrma.org/policy-issues/government-price-setting/value-assessments https://phrma.org/policy-issues/pbms-middlemen https://phrma.org/policy-issues/medicare-medicaid https://phrma.org/policy-issues/medicare-medicaid/medicare-part-d https://phrma.org/policy-issues/medicare-medicaid/medicare-part-b https://phrma.org/policy-issues/safety https://phrma.org/policy-issues/innovation-ecosystem https://phrma.org/policy-issues/patient-access-affordability https://phrma.org/policy-issues/health-insurance https://phrma.org/resources https://phrma.org/resources/forbes-healthcare-summit https://phrma.org/resources/informa-medicaid-drug-rebate-program-summit https://phrma.org/resources/innovation-day-2019 https://phrma.org/resources/live-with-the-19th-prioritizing-mental-health https://phrma.org/resources/making-medicare-work-better-for-patients https://phrma.org/resources/modern-healthcare-leadership-symposium https://phrma.org/resources/pathways-to-patient-affordability https://phrma.org/resources/people-v-cancer https://phrma.org/resources/phrma-media-briefing-at-asco https://phrma.org/resources/reuters-pharma-usa-2024 https://phrma.org/resources/the-art-of-the-possible-reimagining-the-biopharmaceutical-supply-chain https://phrma.org/resources/the-future-of-fighting-cancer https://phrma.org/resources/the-future-of-health-care-summit https://phrma.org/resources/the-future-of-science-how-women-are-leading-medical-innovation https://phrma.org/resources/the-inflation-reduction-act-unfinished-business https://phrma.org/resources/the-post-midterm-health-care-agenda https://phrma.org/resources/the-state-of-care-disrupting-alzheimers https://phrma.org/resources/turning-point-documentary-screening-plus-conversation https://phrma.org/resources/whats-really-driving-the-cost-of-health-care-in-2023 https://phrma.org/resources/patient-assistance https://phrma.org/resources/11-billion-vaccine-doses-in-2021 https://phrma.org/resources/one-pagers-and-infographics https://phrma.org/resources/polling-blogs https://phrma.org/resources/press-room-redirect https://phrma.org/resources/related-resources-out-of-pockets https://phrma.org/resources/costs-in-context-videos-and-graphics https://phrma.org/resources/prescription-medicine-insulin-costs-in-context https://phrma.org/resources/september-2023-polling-doc https://phrma.org/resources/a-delicate-balance_pharmaceutical-innovation-and-access https://phrma.org/resources/bio_phrma-principles-on-responsible-sharing-of-truthful-and-non_misleading-cod15 https://phrma.org/resources/phrma-positions-on-quality-and-performance-measurement https://phrma.org/resources/after-covid-19-preventing-the-next-pandemic https://phrma.org/resources/asco-media-briefing https://phrma.org/resources/bamberg-health-us-northeast-healthcare-innovation-summit https://phrma.org/resources/bridging-the-gap-new-collaborations-to-drive-antimicrobial-innovation https://phrma.org/resources/bridging-the-gender-and-racial-health-gap https://phrma.org/resources/deconstructing-the-prescription-drug-supply-chain https://phrma.org/resources/fierce-biotech-summit https://phrma.org/resources/fierce-jpm-week-2024-patient-affordability-outlook https://phrma.org/resources/fierce-pharmas-jp-morgan-health-care-conference https://phrma.org/resources/better-health-care https://phrma.org/resources/five-reasons-tying-va-prices-to-medicare-part-d-misses-the-mark-september-2021 https://phrma.org/resources/health-care-communications https://phrma.org/resources/phrma-recognizes-2016-research-and-hope-award-recipients https://phrma.org/resources/sources-of-adherence-research-funding https://phrma.org/resources/the-state-of-care-future-of-medicare https://phrma.org/resources/the-state-of-care-patient-access-and-affordability https://phrma.org/resources/media-contacts https://phrma.org/resources/press-room https://phrma.org/resources/state-map https://phrma.org/resources/the-value-collaborative https://phrma.org/resources/340b-morning-consult-polling https://phrma.org/resources/poll-memo-july-2020 https://phrma.org/resources/the-value-collaborative-videos https://phrma.org/resources/vermonts-2016-exchange-plans https://phrma.org/resources/a-day-in-the-life https://phrma.org/resources/resource-library https://phrma.org/resources/card-the-dangers-of-the-latest-drug https://phrma.org/resources/statement-by-imc-amiif-and-phrma-on-promoting-ethics-and-business-integrity-in-healthcare https://phrma.org/resources/emerging-value-in-oncology https://phrma.org/resources/clinical-trial-diversity-principles-executive-summary https://phrma.org/resources/direct-to-consumer-advertising-principles https://phrma.org/resources/phrma-principles-for-clinical-trial-data-sharing https://phrma.org/resources/phrma-principles-for-responsible-clinical-trial-data-sharing-certifications https://phrma.org/resources/a-history-of-medicare https://phrma.org/resources/new-yorks-2016-exchange-plans https://phrma.org/resources/financial-times-us-pharma-and-biotech-summit https://phrma.org/resources/lets-talk-about-cost https://phrma.org/resources/share-the-savings-states https://phrma.org/resources/share-the-savings2 https://phrma.org/resources/poc-share-the-savings-if-insurers-dont-pay-full-price-for-medicines-seniors-shouldnt-either https://phrma.org/resources/the-washington-post-global-womens-summit https://phrma.org/resources/2021-phrma-scholars https://phrma.org/resources/americas-physician-groups-annual-fall-conference https://phrma.org/resources/bamberg-health-north-america-rare-disease-summit https://phrma.org/resources/press-release-launch-of-us-consensus-framework-to-advance-health-equity-and-ethical-collaboration https://phrma.org/resources/industry-profile-2020 https://phrma.org/resources/code-on-interactions-with-health-care-professionals https://phrma.org/resources/the-atlantic-people-v-cancer https://phrma.org/resources/the-rise-of-the-superbugs-tackling-antibiotic-and-antimicrobial-resistance https://phrma.org/resources/phrma-policy-solutions_delivering-innovative-treatments-to-patients https://phrma.org/resources/policy-prescriptions-for-cost-and-coverage https://phrma.org/resources/costs-in-context-videos-and-graphics1 https://phrma.org/resources/reuters-pharma-and-patient-usa-2024 https://phrma.org/resources/the-hill-us-healthcares-annual-checkup https://phrma.org/resources/fierce-jpm-week-addressing-patient-affordability-with-340b https://phrma.org/resources/the-state-of-care-innovation-and-access https://phrma.org/resources/leading-on-value-solutions-for-an-evolving-health-care-system https://phrma.org/resources/phrma-comment-letter-on-cms-proposed-rule https://phrma.org/resources/phrma-principles-on-conduct-of-clinical-trials https://phrma.org/resources/follow-the-data-how-race-ethnicity-travel-through-the-system-and-get-lost-along-the-way https://phrma.org/resources/adherence https://phrma.org/resources/us-consensus-framework-to-advance-ethical-collaboration https://phrma.org/resources/community-guidelines https://phrma.org/resources/industry-economic-impact https://phrma.org/resources/progress-in-treating-diabetes https://phrma.org/resources/stopping-the-spread-of-ebola https://phrma.org/resources/ifpma-right-rail https://phrma.org/resources/justine-dellaringa https://phrma.org/resources/terri-foy https://phrma.org/resources/americas-biopharmaceutical-companies-continue-to-expand-advanced-manufacturing-across-the-country https://phrma.org/resources/americas-biopharmaceutical-companies https://phrma.org/resources/applying-icer-assessments-alaska-fact-sheet https://phrma.org/resources/applying-icer-assessments-california-fact-sheet https://phrma.org/resources/applying-icer-assessments-colorado-fact-sheet https://phrma.org/resources/applying-icer-assessments-connecticut-fact-sheet https://phrma.org/resources/applying-icer-assessments-maryland-fact-sheet https://phrma.org/resources/applying-icer-assessments-massachusetts-fact-sheet https://phrma.org/resources/applying-icer-assessments-minnesota-fact-sheet https://phrma.org/resources/applying-icer-assessments-nevada-fact-sheet https://phrma.org/resources/applying-icer-assessments-new-mexico-fact-sheet https://phrma.org/resources/applying-icer-assessments-new-york-fact-sheet https://phrma.org/resources/applying-icer-assessments-oregon-fact-sheet https://phrma.org/resources/applying-icer-assessments-texas-fact-sheet https://phrma.org/resources/applying-icer-assessments-washington-fact-sheet https://phrma.org/resources/barriers-between-black-patients-and-their-health-care https://phrma.org/resources/bsufaiii https://phrma.org/resources/closing-the-gender-gap-in-innovation-the-biopharmaceutical-industry-leads-the-way https://phrma.org/resources/colorado-share-the-savings-one-pager https://phrma.org/resources/debunking-the-false-narrative-about-biopharmaceutical-patents https://phrma.org/resources/driving-medical-innovation-and-patient-access-through-the-indo-pacific-economic-framework https://phrma.org/resources/executive-summary-comment-letter-to-hhs-on-blueprint-to-lower-drug-prices-and-reduce-out-of-pocket-costs https://phrma.org/resources/four-things-affecting-the-hispanic-patient-experience https://phrma.org/resources/getting-the-facts-straight-on-medicare-part-b-and-the-proposed-international-pricing-index-model https://phrma.org/resources/government-price-setting-policies-do-not-address-systemic-health-equity-issues https://phrma.org/resources/health-insurance-companies-and-pharmacy-benefit-managers-pose-barriers-to-care https://phrma.org/resources/hold-pbms-accountable-rein-in-middlemen-tactics-that-harm-patients https://phrma.org/resources/impact-of-industry-sponsored-clinical-trials https://phrma.org/resources/infographic-how-medicine-purchased-at-a-canadian-internet-pharmacy-could-actually-be-fake https://phrma.org/resources/out-of-pocket-trends-in-medicare-part-d-show-rising-costs-for-seniors https://phrma.org/resources/the-dangers-of-government-negotiation https://phrma.org/resources/3rd-annual-pathways-to-success-virtual-graduate-summit-and-career-expo https://phrma.org/resources/addressing-the-unmet-medical-needs-of-older-americans https://phrma.org/resources/americas-biopharmaceutical-research-companies-are-committed-to-fighting-mental-illness https://phrma.org/resources/by-the-numbers-340b-is-driving-up-health-care-costs https://phrma.org/resources/government-negotiation-threatens-access-to-medicines https://phrma.org/resources/government-price-setting-threatens-patient-access-to-treatments https://phrma.org/resources/government-price-setting-threatens-the-many-significant-innovations-generated-after-initial-fda-approval https://phrma.org/resources/implications-of-speaker-pelosis-drug-pricing-plan https://phrma.org/resources/making-coupons-count-a-case-study-for-patients-with-hiv https://phrma.org/resources/phrma-letter-to-hrsa-and-hhs-regarding-duplicate-discounting-in-340b https://phrma.org/resources/the-dangers-of-the-latest-drug-pricing-plan-in-the-reconciliation-package https://phrma.org/resources/value-based-contracts-2009-q2-2019 https://phrma.org/resources/2020-industry-profile-toolkit-preparing-for-the-next-public-health-emergency-antimicrobial-resistance https://phrma.org/resources/2019-industry-profile-toolkit-10-things-you-should-know-about-medicine-spending-and-costs https://phrma.org/resources/2019-industry-profile-toolkit-better-use-of-medicines-can-improve-health-outcomes-and-reduce-the-use-of-costly-medical-care https://phrma.org/resources/2019-industry-profile-toolkit-government-mandated-price-controls-harm-patients-and-undermine-innovation https://phrma.org/resources/2019-industry-profile-toolkit-hospital-consolidation-increases-health-care-costs-for-patients-and-the-healthcare-system https://phrma.org/resources/2019-industry-profile-toolkit-ip-incentives-fuel-biopharmaceutical-innovation-and-competition https://phrma.org/resources/2019-industry-profile-toolkit-medicines-are-transforming-the-trajectory-of-many-diseases https://phrma.org/resources/2019-industry-profile-toolkit-the-biopharmaceutical-industry-fuels-the-economy-and-global-competitiveness https://phrma.org/resources/2019-industry-profile-toolkit-the-dynamic-u-s-research-and-development-ecosystem https://phrma.org/resources/2019-industry-profile-toolkit-the-importance-of-strong-trade-agreements-in-driving-biopharmaceutical-innovation https://phrma.org/resources/2019-industry-profile-toolkit-understanding-the-pharmaceutical-distribution-and-payment-system-and-how-it-could-work-better-for-patients https://phrma.org/resources/2020-industry-profile-toolkit-10-things-you-should-know-about-medicine-spending-and-costs https://phrma.org/resources/2020-industry-profile-toolkit-2020-importance-of-trade-agreements https://phrma.org/resources/2020-industry-profile-toolkit-better-use-of-medicines-can-improve-health-outcomes-and-reduce-the-use-of-costly-medical-care https://phrma.org/resources/2020-industry-profile-toolkit-ensuring-the-safety-and-continuity-of-the-drug-supply-chain https://phrma.org/resources/2020-industry-profile-toolkit-how-the-us-health-care-system-can-better-accommodate-cell-and-gene-therapies https://phrma.org/resources/2020-industry-profile-toolkit-innovative-contracting-opportunities-and-challenges https://phrma.org/resources/2020-industry-profile-toolkit-medicines-are-transforming-the-trajectory-of-many-diseases https://phrma.org/resources/2020-industry-profile-toolkit-the-biopharmaceutical-industry-fueling-the-economy-and-global-competitiveness https://phrma.org/resources/2020-industry-profile-toolkit-the-biopharmaceutical-research-ecosystem https://phrma.org/resources/2020-industry-profile-toolkit-the-dynamic-us-research-and-development-ecosystem https://phrma.org/resources/2021-industry-profile-toolkit-10-things-you-should-know-about-medicine-spending-and-costs https://phrma.org/resources/2021-industry-profile-toolkit-better-use-of-medicines-can-improve-health-outcomes-and-reduce-the-use-of-costly-medical-care https://phrma.org/resources/2021-industry-profile-toolkit-government-price-setting-threatens-access-to-medicines https://phrma.org/resources/2021-industry-profile-toolkit-how-the-us-health-care-system-can-better-accommodate-cell-and-gene-therapies https://phrma.org/resources/2021-industry-profile-toolkit-innovative-contracting-opportunities-and-challenges https://phrma.org/resources/2021-industry-profile-toolkit-making-medicines-more-affordable-for-commercially-insured-patients-and-medicare-beneficiaries https://phrma.org/resources/2021-industry-profile-toolkit-preserving-the-340b-program-and-protecting-the-safety-net https://phrma.org/resources/2021-industry-profile-toolkit-the-biopharmaceutical-industrys-role-in-fueling-the-us-economy-and-global-competitiveness https://phrma.org/resources/2021-industry-profile-toolkit-the-biopharmaceutical-research-ecosystem https://phrma.org/resources/2021-industry-profile-toolkit-the-dynamic-us-research-and-development-ecosystem https://phrma.org/resources/2021-industry-profile-toolkit-the-importance-of-strong-trade-policy-in-driving-biopharmaceutical-innovation https://phrma.org/resources/2022-industry-profile-toolkit-the-340b-program-once-a-safety-net-program-now-a-program-that-fails-vulnerable-patients https://phrma.org/resources/340b-the-federal-safety-net-program-benefitting-everyone-but-patients https://phrma.org/resources/340b-the-unintentional-profit-stream-that-was-supposed-to-help-patients https://phrma.org/resources/4-things-to-know-about-340b-and-contract-pharmacies https://phrma.org/resources/4-things-to-know-about-biopharmaceutical-efforts-to-fight-cancer https://phrma.org/resources/4-things-you-need-to-know-about-marketing-and-promotion-of-medicines https://phrma.org/resources/ads https://phrma.org/resources/americans-with-mental-health-conditions-face-administrative-and-financial-barriers-to-care-pes-3 https://phrma.org/resources/americans-with-mental-health https://phrma.org/resources/how-will-international-reference-pricing-affect-you https://phrma.org/resources/biopharmaceutical-trade-supports-americas-economy-and-a-large-diverse-workforce https://phrma.org/resources/making-coupons-count-for-patients-at-the-pharmacy-counter https://phrma.org/resources/3-things-that-support-robust-biopharmaceutical-research-and-development https://phrma.org/resources/accelerated-approval-bringing-patients-access-to-needed-medicines https://phrma.org/resources/biopharmaceutical-innovation-in-fighting-hiv-aids https://phrma.org/resources/4-truths-about-state-government-price-setting https://phrma.org/resources/antimicrobial-resistance-a-growing-public-health-threat https://phrma.org/resources/2022-morning-consult-state-poll-health-care-issues-and-policy-solutions https://phrma.org/resources/explainer-vertical-integration-may-allow-insurers-to-skirt-medical-loss-ratio-requirements https://phrma.org/resources/how-icer-assessment-of-new-migraine-treatments-ignores-patient-needs https://phrma.org/resources/how-the-340b-program-is-contributing-to-health-inequities https://phrma.org/resources/americans-reject-medicare-negotiation-and-government-price-setting https://phrma.org/resources/infographics-on-obtaining-patents-and-maintaining-patents https://phrma.org/resources/2021-industry-profile-toolkit-medicines-are-transforming-the-trajectory-of-many-diseases https://phrma.org/resources/2021-industry-profile-toolkit-preparing-for-the-next-public-health-emergency-amr https://phrma.org/resources/infographic-the-realities-of-drug-importation-from-canada https://phrma.org/resources/infographic-voters-frustrated-by-hurdles-imposed-by-health-insurance-companies-and-pharmacy-benefit-managers https://phrma.org/resources/international-reference-pricing-outsources-decisions-about-americans-medicines-and-health https://phrma.org/resources/key-findings-from-the-patient-experience-survey https://phrma.org/resources/lessons-learned-from-europe-price-setting-policies-erode-biopharmaceutical-leadership https://phrma.org/resources/making-medicines-more-affordable https://phrma.org/resources/marketing-and-promotion-of-medicines-4-things-you-need-to-know https://phrma.org/resources/mat-one-pager-espanol https://phrma.org/resources/mat-one-pager https://phrma.org/resources/may-2024-registered-voter-survey-results https://phrma.org/resources/medicaid-by-the-numbers https://phrma.org/resources/meet-mat-brochure https://phrma.org/resources/michigan-share-the-savings-one-pager https://phrma.org/resources/morning-consult-september-2024-registered-voter-survey https://phrma.org/resources/nearly-half-of-every-dollar-spent-on-medicines-goes-to-someone-who-doesnt-make-them https://phrma.org/resources/nevada-share-the-savings-one-pager https://phrma.org/resources/new-hampshire-share-the-savings-one-pager https://phrma.org/resources/new-survey-americans-overwhelming-support-strong-reforms-that-rein-in-pbm-abuses https://phrma.org/resources/ohio-share-the-savings-one-pager https://phrma.org/resources/patient-experience-survey-insurer-and-pbm-imposed-barriers-stand-between-patients-and-health-care https://phrma.org/resources/patient-journey-through-a-technology-driven-health-care-system https://phrma.org/resources/patients-deserve-better-than-treatment-delays https://phrma.org/resources/pdufa-vi https://phrma.org/resources/phrma-comment-call-for-public-input-on-icer-value-framework https://phrma.org/resources/phrma-member-companies-raise-concerns-with-impact-of-proposed-international-pricing-index-model https://phrma.org/resources/phrma-usmca-fact-sheet https://phrma.org/resources/prescriber-requirements-to-help-combat-the-opioid-crisis https://phrma.org/resources/protect-copay-assistance-end-insurer-and-middlemen-games-that-drive-up-costs-for-patients https://phrma.org/resources/realities-of-importation https://phrma.org/resources/rfi-comments-on-hhs-blueprint-to-lower-drug-prices-and-reduce-out-of-pocket-costs https://phrma.org/resources/setting-the-record-straight-on-the-bayh-dole-act-and-march-in https://phrma.org/resources/sharing-negotiated-savings-with-patients-at-the-pharmacy-counter https://phrma.org/resources/sharing-rebates-can-save-americans-with-diabetes-500-each-year-and-improve-adherence https://phrma.org/resources/significant-pharmaceutical-backlogs-remain-in-brazil https://phrma.org/resources/south-carolina-share-the-savings-one-pager https://phrma.org/resources/standardized-plans-can-improve-access-to-medicines https://phrma.org/resources/testimony-of-lori-m-reilly-perspectives-on-the-340b-drug-discount-program https://phrma.org/resources/the-danger-of-waiving-trips-intellectual-property-rights-at-the-wto https://phrma.org/resources/the-dangers-of-h-r-3 https://phrma.org/resources/the-ira-could-lead-to-higher-out-of-pocket-costs-for-3-and-a-half-million-medicare-patients-in-2026 https://phrma.org/resources/the-potential-economic-impacts-of-a-significant-shift-in-us-biopharmaceutical-industry-revenues https://phrma.org/resources/the-united-states-vs-other-countries-availability-of-cancer-medicines-varies https://phrma.org/resources/the-united-states-vs-other-countries-availability-of-new-medicines-varies https://phrma.org/resources/the-united-states-vs-other-countries-availability-of-part-b-medicines-varies https://phrma.org/resources/the-us-market-for-biosimilars-and-biologics-medicines https://phrma.org/resources/three-things-to-know-about-how-insurers-and-pbms-impose-barriers-to-care-for-mental-health-patients https://phrma.org/resources/transforming-biopharmaceutical-research-and-development-through-digital-health https://phrma.org/resources/washington-share-the-savings-one-pager https://phrma.org/resources/what-is-government-price-setting https://phrma.org/resources/what-voters-are-looking-for-this-election-cycle https://phrma.org/resources/who-pandemic-agreement-pros-and-cons-for-us-innovation https://phrma.org/resources/wto-twelfth-ministerial-conference https://phrma.org/resources/for-profit-pharmacies-make-billions-off-340b-program-without-clear-benefit-to-patients https://phrma.org/resources/value-assessments-should-include-all-the-outcomes-that-matter-to-patients-and-families https://phrma.org/resources/the-biosimilar-red-tape-elimination-act-provides-a-new-profit-source-for-pbms https://phrma.org/resources/pediatric-drug-development-issue-brief-progress-in-a-critical-but-challenging-space https://phrma.org/resources/stop-pharmacy-benefit-managers-from-gaming-the-system https://phrma.org/resources/pocket-card-what-is-pdufa https://phrma.org/resources/patient-experience-survey-protecting-lifelines-to-access-and-innovation https://phrma.org/resources/spurring-innovation-in-rare-diseases https://phrma.org/resources/innovative-contracts-2009-2021 https://phrma.org/resources/morning-consult-national-poll-may-2024 https://phrma.org/resources/supply-chain-backgrounder https://phrma.org/resources/share-the-savings-if-insurers-dont-pay-full-price-for-medicines-seniors-shouldnt-either https://phrma.org/resources/medicare-prescription-payment-plan-overview-for-health-care-providers https://phrma.org/resources/regulatory-data-protection-promotes-biopharmaceutical-innovation-and-patient-access https://phrma.org/resources/medicare-part-d-fact-sheets https://phrma.org/resources/the-long-uncertain-and-expensive-road-for-biopharmaceutical-startups https://phrma.org/resources/the-public-health-success-of-vaccines https://phrma.org/resources/understanding-prescription-drug-shortages https://phrma.org/resources/the-ahip-premium-dollar-corrected https://phrma.org/resources/2017-u-s-biopharmaceutical-exports https://phrma.org/resources/2018-u-s-biopharmaceutical-exports https://phrma.org/resources/2020-us-biopharmaceutical-exports https://phrma.org/resources/340b-spotlight-myth-vs-fact https://phrma.org/resources/a-patients-journey-an-example-of-accessing-new-alzheimers-treatments-through-medicare-part-b https://phrma.org/resources/accumulator-adjustment-programs-from-payers-lead-to-surprise-out-of-pocket-costs-and-nonadherence https://phrma.org/resources/americans-support-protecting-us-intellectual-property-and-innovation https://phrma.org/resources/arthritis-case-study-personalized-vs-general-treatment https://phrma.org/resources/cancer-moonshot-print-ad https://phrma.org/resources/foreign-threats-to-american-intellectual-property https://phrma.org/resources/hospitals-make-9-times-more-than-physicians-offices-on-provider-administered-medicines https://phrma.org/resources/infographic-on-addressing-amr https://phrma.org/resources/lets-talk-about-medicare-ad-diabetes https://phrma.org/resources/robust-competition-in-the-us-market-balances-affordability-and-innovation https://phrma.org/resources/the-success-of-bayh-dole https://phrma.org/resources/public-private-collaboration-fuels-the-us-biopharmaceutical-ecosystem https://phrma.org/resources/follow-the-dollar-graphics https://phrma.org/resources/340b-covered-entities-and-for-profit-corporations-capturing-massive-profit-margins-on-medicines-dispensed-through-contract-pharmacies https://phrma.org/resources/the-dangers-of-drug-importation https://phrma.org/resources/medicine-development-in-a-complex-collaborative-ecosystem https://phrma.org/resources/share-the-savings https://phrma.org/resources/340b-then-and-now https://phrma.org/resources/more-than-half-of-patients-out-of-pocket-spending-for-brand-medicines-is-based-on-list-price https://phrma.org/resources/10-things-you-should-know-about-medicine-spending-and-costs https://phrma.org/resources/follow-the-dollar-flow-of-payment-for-a-3000-hiv-medicine https://phrma.org/resources/follow-the-dollar-flow-of-payment-for-a-100-blood-pressure-medicine https://phrma.org/resources/phrma-comment-medical-product-communications-that-are-consistent-with-the-fda-required-labeling-questions-and-answers https://phrma.org/resources/january-2024-morning-consult-poll-about-trips-waiver-expansion https://phrma.org/resources/the-inflation-reduction-act-discourages-vital-r-and-d-in-cancer-medicines https://phrma.org/resources/understanding-prescription-medicine-spending https://phrma.org/resources/the-vaccine-life-cycle-safety-at-every-phase https://phrma.org/resources/research-shows-voters-support-rebate-rule https://phrma.org/resources/phrma-amicus-brief-with-the-us-supreme-court-in-support-of-fda https://phrma.org/resources/phrma-comment-letter-on-oig-safe-harbor-proposed-rule https://phrma.org/resources/phrma-comments-to-national-institutes-of-health-transforming-discoveries-into-products-maximizing-nihs-levers-to-catalyze-technology-transfer https://phrma.org/resources/phrma-comments-to-the-2019-national-trade-estimate-report https://phrma.org/resources/phrma-comments-to-the-2020-national-trade-estimate-report https://phrma.org/resources/phrma-comments-to-the-2021-national-trade-estimate-report https://phrma.org/resources/phrma-comments-to-the-part-d-6pc-proposed-rule https://phrma.org/resources/phrma-comments-to-ustr-on-the-us-taiwan-initiative-on-21st-century-trade https://phrma.org/resources/phrma-files-amicus-brief-with-the-us-court-of-appeals-for-the-fifth-circuit-in-support-of-fda https://phrma.org/resources/phrma-japan-industry-vision-report https://phrma.org/resources/phrma-special-301-submission-2018 https://phrma.org/resources/phrma-special-301-submission-2020 https://phrma.org/resources/phrma-special-301-submission-2021 https://phrma.org/resources/phrma-special-301-submission-2022 https://phrma.org/resources/phrma-special-301-submission-2023 https://phrma.org/resources/promoting-a-proactive-policy-agenda https://phrma.org/resources/phrma-comments-on-the-negotiating-objectives-for-a-us-japan-trade-agreement https://phrma.org/resources/phrma-files-amicus-brief-with-us-court-of-appeals-in-support-of-fda https://phrma.org/resources/86-of-aarp-members-support-the-medicare-rebate-rule-that-aarp-opposes https://phrma.org/resources/amgen-ceo-robert-a-bradway-becomes-phrma-board-chairman https://phrma.org/resources/analysis-finds-higher-outpatient-drug-spending-at-340b-hospitals https://phrma.org/resources/biopharmaceutical-industry-takes-bold-new-policy-position-on-how-payments-should-work https://phrma.org/resources/analysis-shows-how-insurers-and-middlemen-drive-up-out-of-pocket-costs-for-patients-at-the-pharmacy https://phrma.org/resources/avaleres-elizabeth-carpenter-to-join-phrma-as-evp-for-policy-and-research https://phrma.org/resources/daniel-o-day-new-chair-of-phrma-board https://phrma.org/resources/eight-in-10-registered-voters-support-requiring-health-insurance https://phrma.org/resources/eli-lilly-and-company-chairman-and-ceo-david-ricks-becomes-phrma-board-chairman https://phrma.org/resources/equitable-breakthroughs-in-medicine-development-reaches-next-phase-driving-diversity-in-clinical-trials-in-georgia-south-carolina-tennessee-and-texas https://phrma.org/resources/final-benefits-and-payment-rule-a-win-for-patients https://phrma.org/resources/five-key-strategies-for-enhancing-diversity-in-clinical-trials https://phrma.org/resources/hospital-practices-increase-costs-of-medicines-for-patients-and-employers-new-report-shows https://phrma.org/resources/house-drug-pricing-plan-will-throw-sand-in-the-gears-of-medical-progress https://phrma.org/resources/latest-drug-pricing-proposal-not-the-balanced-approach-we-need https://phrma.org/resources/misleading-drug-pricing-report-fails-to-address-real-affordability-challenges-patients-face https://phrma.org/resources/nearly-1-in-5-hospitals-marks-up-medicine-prices-at-least-700-percent https://phrma.org/resources/neurocrine-biosciences-joins-phrma https://phrma.org/resources/nevada-addresses-sb-539s-most-significant-flaws https://phrma.org/resources/new-analysis-finds-more-than-half-of-brand-medicine-spending-goes-to-the-supply-chain-middlemen-and-other-stakeholders https://phrma.org/resources/new-analysis-finds-nearly-50-percent-of-brand-medicine-spending-goes-to-the-supply-chain-and-others https://phrma.org/resources/new-analysis-inflation-reduction-act-undermines-cancer-medicine-development https://phrma.org/resources/new-analysis-shows-340b-hospitals-with-highest-operating-margins-provide-lowest-levels-charity-care https://phrma.org/resources/new-analysis-shows-contract-pharmacies-financially-gain-from-340b-program-with-no-clear-benefit-to-patients https://phrma.org/resources/new-analysis-shows-hospitals-mark-up-medicine-prices-500-percent https://phrma.org/resources/new-analysis-the-ira-could-lead-to-higher-out-of-pocket-costs-for-3-point-5-million-medicare-patients https://phrma.org/resources/new-data-show-340b-hospitals-are-reimbursed-on-average-three-times-what-they-pay-for-medicines https://phrma.org/resources/new-ipsos-poll-shows-americans-are-frustrated-with-abusive-insurance-practices-that-exacerbate-access-and-affordability-challenges https://phrma.org/resources/new-let-s-talk-about-cost-ads-highlight-how-copay-accumulator-programs-leave-patients-financially-exposed https://phrma.org/resources/new-milliman-analysis-finds-insulin-costs-20-percent-less-today-than-in-2007 https://phrma.org/resources/new-poll-shows-that-support-for-medicare-negotiation-plummets-once-americans-learn-about-the-policy-arguments https://phrma.org/resources/new-report-finds-largest-pbms-restrict-access-to-more-than-1150-medicines https://phrma.org/resources/new-survey-reveals-insurance-design-leads-to-access-and-affordability-issues-for-most-vulnerable-patients https://phrma.org/resources/phrma-2018-special-301-submission-calls-for-urgent-action-to-address-serious-access-and-ip-barriers https://phrma.org/resources/phrma-2020-special-301-report-urges-ustr-to-protect-us-innovation https://phrma.org/resources/phrma-applauds-courts-decision-to-strike-down-patient-assistance-penalty https://phrma.org/resources/phrma-appoints-ambassador-hans-klemm-as-new-japan-representative https://phrma.org/resources/phrma-appoints-new-leadership-to-board-of-directors https://phrma.org/resources/phrma-comments-on-the-negotiating-objectives-for-a-us-european-union-trade-agreement https://phrma.org/resources/phrma-comments-to-ustr-regarding-us-uk-trade-agreement https://phrma.org/resources/phrma-decries-damaging-foreign-practices-in-special-301-filing https://phrma.org/resources/phrma-files-amicus-brief-with-us-supreme-court-in-support-of-fda https://phrma.org/resources/phrma-joins-top-academic-leaders-to-announce-new-community-based-initiative-to-enhance-clinical-trial-diversity https://phrma.org/resources/phrma-litigation-asserts-340b-administrative-dispute-resolution-final-rule-is-unlawful-and-unconstitutional https://phrma.org/resources/phrma-makes-down-payment-on-las-growing-bioscience-sector https://phrma.org/resources/phrma-members-take-new-approach-to-dtc-television-advertising https://phrma.org/resources/phrma-names-anne-esposito-senior-vice-president-of-federal-advocacy https://phrma.org/resources/phrma-names-jennifer-bryant-executive-vice-president-of-policy-and-research https://phrma.org/resources/phrma-names-lori-reilly-chief-operating-officer https://phrma.org/resources/phrma-responds-to-hhs-dtc-rule-launches-website-providing-patients-with-cost-information https://phrma.org/resources/phrma-s-roadmap-to-health-program-makes-first-stop-in-the-bronx-with-nys-assembly-member-marcos-crespo-and-new-york-health-works https://phrma.org/resources/phrma-shares-condolences-upon-the-death-of-former-japanese-prime-minister-shinzo-abe https://phrma.org/resources/phrma-special-301-submission-2019 https://phrma.org/resources/phrma-statement-on-340b-access-act https://phrma.org/resources/phrma-statement-on-administration-s-drug-importation-scheme https://phrma.org/resources/phrma-statement-on-administrations-importation-plan https://phrma.org/resources/phrma-statement-on-administrations-part-d-senior-savings-model https://phrma.org/resources/phrma-statement-on-biosimilars-action-plan https://phrma.org/resources/phrma-statement-on-cms-final-guidance-on-the-price-setting-provisions-in-the-ira https://phrma.org/resources/phrma-statement-on-cms-initial-price-setting-offer-to-biopharmaceutical-companies https://phrma.org/resources/phrma-statement-on-comments-to-cms-regarding-proposed-part-d-rule-and-rfi-exploring-pass-through-rebates-to-seniors-at-point-of-sale https://phrma.org/resources/phrma-statement-on-congressional-user-fees-agreement https://phrma.org/resources/phrma-statement-on-democrats-drug-pricing-deal-in-reconciliation-package https://phrma.org/resources/phrma-statement-on-drug-pricing-executive-orders https://phrma.org/resources/phrma-statement-on-efforts-to-support-real-world-evidence https://phrma.org/resources/phrma-statement-on-fda-authorizing-floridas-importation-plan https://phrma.org/resources/phrma-statement-on-fda-draft-guidance-on-clinical-trials https://phrma.org/resources/phrma-statement-on-first-list-of-medicines-subject-to-government-price-setting https://phrma.org/resources/phrma-statement-on-florida-importation-proposal https://phrma.org/resources/phrma-statement-on-government-price-setting-in-medicare-part-d https://phrma.org/resources/phrma-statement-on-help-act https://phrma.org/resources/phrma-statement-on-hhs-speech-and-part-b-proposal https://phrma.org/resources/phrma-statement-on-house-leadership-partisan-drug-pricing-proposal https://phrma.org/resources/phrma-statement-on-house-passage-of-reconciliation-spending-bill https://phrma.org/resources/phrma-statement-on-house-passage-of-the-patient-protection-and-affordable-care-enhancement-act https://phrma.org/resources/phrma-statement-on-house-pbm-transparency-bills https://phrma.org/resources/phrma-statement-on-jama-clinical-trials-study https://phrma.org/resources/phrma-statement-on-latest-drug-pricing-proposal https://phrma.org/resources/phrma-statement-on-new-cms-medicaid-guidance https://phrma.org/resources/americans-sound-the-alarm-on-abusive-insurance-practices-and-call-for-and-patient-centered-solutions https://phrma.org/resources/august-polling-data-update-2 https://phrma.org/resources/chart-pack-cancer-medicines-value-in-context https://phrma.org/resources/chart-pack-medicines-in-340b https://phrma.org/resources/pwc-fy2022-budget-revenue-effects https://phrma.org/resources/2017-direct-to-consumer-advertising-survey-results https://phrma.org/resources/2021-voter-solutions-data https://phrma.org/resources/2022-mrp-polling-data https://phrma.org/resources/2022-national-trade-estimate-report-on-foreign-trade-barriers-nte https://phrma.org/resources/2024-national-trade-estimate-report-on-foreign-trade-barriers-nte https://phrma.org/resources/a-decade-of-innovation-in-rare-diseases https://phrma.org/resources/a-look-at-company-efforts-to-enhance-clinical-trial-diversity https://phrma.org/resources/addressing-the-growing-crises-of-mental-health-and-substance-use-disorders-in-the-united-states https://phrma.org/resources/advancing-analytical-methodologies-for-unmeasured-confounding-in-real-world-evidence https://phrma.org/resources/american-viewpoint-survey-march-2022 https://phrma.org/resources/americans-managing-an-autoimmune-condition-face-administrative-and-financial-barriers-to-care https://phrma.org/resources/americans-want-a-bipartisan-approach-to-tackle-health-care-affordability-and-coverage-issues https://phrma.org/resources/analysis-of-access-restrictions-to-new-medicines-in-the-united-kingdom https://phrma.org/resources/april-2021-polling-data https://phrma.org/resources/april-2023-polling-data https://phrma.org/resources/april-consumer-polling-data https://phrma.org/resources/august-2021-polling-data-medicare https://phrma.org/resources/researching-cancer-medicines https://phrma.org/resources/report-insurance-barriers-contribute-to-health-disparities-among-commercially-insured-americans https://phrma.org/resources/follow-the-dollar-report https://phrma.org/resources/a-sustained-commitment-to-advancing-diversity-equity-and-inclusion https://phrma.org/resources/applying-icer-assessments-in-medicaid-could-limit-patients-access-to-medicines https://phrma.org/resources/practical-solutions-for-americans-true-affordability-concerns https://phrma.org/resources/2017-state-of-vaccines https://phrma.org/resources/new-era-of-medicine-vaccines https://phrma.org/resources/phrma-statement-on-nih-heal-partnership-committee https://phrma.org/resources/phrma-statement-on-part-d-provision-in-budget-deal https://phrma.org/resources/phrma-statement-on-passage-of-prescription-drug-board-in-the-minnesota-legislature https://phrma.org/resources/phrma-statement-on-pasteur-act-introduction https://phrma.org/resources/phrma-statement-on-patent-trial-and-appeal-board-reform-act-of-2022 https://phrma.org/resources/phrma-statement-on-political-giving https://phrma.org/resources/phrma-statement-on-president-bidens-remarks-to-lower-prescription-drug-prices https://phrma.org/resources/phrma-statement-on-president-bidens-state-of-the-union-address https://phrma.org/resources/phrma-statement-on-president-trumps-drug-pricing-blueprint https://phrma.org/resources/phrma-statement-on-presidents-fy2019-budget https://phrma.org/resources/phrma-statement-on-proposed-march-in-framework https://phrma.org/resources/phrma-statement-on-signing-the-us-mexico-canada-agreement-usmca https://phrma.org/resources/phrma-statement-on-speaker-pelosi-s-radical-plan https://phrma.org/resources/phrma-statement-on-tennessee-medicaid-demonstration https://phrma.org/resources/phrma-statement-on-the-340b-drug-pricing-program https://phrma.org/resources/phrma-statement-on-the-administrations-proposed-rule-to-reform-the-rebate-system https://phrma.org/resources/phrma-statement-on-the-buy-american-executive-order https://phrma.org/resources/phrma-statement-on-the-eu-pharmaceutical-legislation https://phrma.org/resources/phrma-statement-on-the-fda-and-latest-us-supreme-court-decision https://phrma.org/resources/phrma-statement-on-the-hatch-waxman-integrity-act-of-2019 https://phrma.org/resources/phrma-statement-on-the-indo-pacific-economic-framework https://phrma.org/resources/phrma-statement-on-the-inflation-reduction-act-becoming-law https://phrma.org/resources/phrma-statement-on-the-nomination-of-dr-robert-califf-to-lead-the-us-food-and-drug-administration https://phrma.org/resources/phrma-statement-on-the-presidents-budget-for-fiscal-year-2024 https://phrma.org/resources/phrma-statement-on-the-proposed-biosimilar-user-fee-act-iii-performance-goals-letter https://phrma.org/resources/phrma-statement-on-the-proposed-prescription-drug-user-fee-act-vii-performance-goals-letter https://phrma.org/resources/phrma-statement-on-the-senate-finance-committee-hearing-on-drug-pricing https://phrma.org/resources/phrma-statement-on-the-state-of-the-union-address https://phrma.org/resources/phrma-statement-on-the-trips-waiver-agreement https://phrma.org/resources/phrma-statement-on-the-united-states-mexico-canada-agreement https://phrma.org/resources/phrma-statement-on-the-united-states-mexico-canada-agreement-2019 https://phrma.org/resources/phrma-statement-on-the-war-in-ukraine https://phrma.org/resources/phrma-statement-on-us-international-trade-commission-report-on-expanding-the-trips-waiver https://phrma.org/resources/phrma-statement-on-us-supreme-court-decision-impacting-fda-drug-approval https://phrma.org/resources/phrma-statement-on-user-fee-legislative-text https://phrma.org/resources/phrma-statement-on-white-house-cancer-moonshot-event https://phrma.org/resources/phrma-statement-on-white-house-drug-pricing-event https://phrma.org/resources/phrma-statement-on-wto-trips-waiver-negotiations https://phrma.org/resources/phrma-statement-opposing-senate-finance-committee-drug-pricing-legislation https://phrma.org/resources/phrma-welcomes-2019-special-301-report https://phrma.org/resources/phrma-welcomes-genentech-and-gilead-sciences-to-association https://phrma.org/resources/phrma-welcomes-genmab-to-the-association https://phrma.org/resources/phrmas-debra-deshong-announces-she-is-stepping-down-to-pursue-new-opportunities https://phrma.org/resources/phrmas-steve-ubl-cbo-report-makes-clear-patients-face-future-with-less-hope-under-congress-drug-pricing-plan https://phrma.org/resources/phrmas-steve-ubl-congratulates-xavier-becerra https://phrma.org/resources/phrmas-steve-ubl-describes-ken-frazier-as-a-pivotal-leader-in-the-biopharma-research-industry https://phrma.org/resources/phrmas-steve-ubl-says-white-house-drug-pricing-proposal-not-a-serious-plan-to-lower-what-patients-pay https://phrma.org/resources/phrmas-ubl-calls-senate-passage-of-partisan-drug-pricing-plan-a-tragic-loss-for-patients https://phrma.org/resources/press-release-nica-gcca-phrma-litigation-asserts-price-setting-provisions-in-the-inflation-reduction-act-are-unconstitutional https://phrma.org/resources/robert-zirkelbach-returns-to-leadership-role-at-phrma https://phrma.org/resources/sanofi-ceo-olivier-brandicourt-becomes-phrma-board-chairman https://phrma.org/resources/seniors-patients-taking-prescription-medicines-reject-government-negotiation-when-they-learn-about-consequences-according-to-new-ipsos-poll https://phrma.org/resources/sharing-negotiated-discounts-at-the-pharmacy-counter-could-save-seniors-with-diabetes-more-than-350-annually https://phrma.org/resources/statement-on-litigation-challenging-constitutionality-of-minnesotas-hf-3100 https://phrma.org/resources/statement-on-litigation-challenging-constitutionality-of-oregons-hb-4005-and-hb-2658 https://phrma.org/resources/statement-on-litigation-challenging-legality-of-the-administrations-most-favored-nation-rule https://phrma.org/resources/statement-on-phrma-litigation-challenging-constitutionality-of-provisions-in-arkansas-act-1103 https://phrma.org/resources/steve-tilton-returns-to-phrma-as-senior-vice-president-of-federal-advocacy https://phrma.org/resources/takeda-pharmaceuticals-usa-president-ramona-sequeira-becomes-phrma-board-chair-elect https://phrma.org/resources/takedas-ramona-sequeira-becomes-board-chair-of-phrma https://phrma.org/resources/the-pasteur-act-a-meaningful-policy-reform https://phrma.org/resources/vaccine-approval-important-step-forward-against-pandemic https://phrma.org/resources/vas-narasimhan-of-novartis-becomes-chair-of-phrma-board https://phrma.org/resources/bristol-myers-squibb-ceo-giovanni-caforio-becomes-phrma-board-chairman https://phrma.org/resources/data-show-over-half-of-patients-out-of-pocket-spending-for-brand-medicines-is-based-on-list-price https://phrma.org/resources/new-report-shows-how-supply-chain-shapes-brand-name-medicine-prices https://phrma.org/resources/phrma-statement-on-president-trumps-signing-of-pdufa-vi-reauthorization https://phrma.org/resources/in-honor-of-visionary-leader-phrma-announces-the-kenneth-c-frazier-phrma-scholars-program https://phrma.org/resources/alzheimer-s-medicines-setbacks-and-stepping-stones https://phrma.org/resources/speaker-pelosis-drug-pricing-plan-could-result-in-56-fewer-new-medicines-over-10-years https://phrma.org/resources/july-2021-polling-data https://phrma.org/resources/july-value-polling-data https://phrma.org/resources/june-omi-polling-data https://phrma.org/resources/march-2022-phrma-letter-to-senator-elizabeth-warren https://phrma.org/resources/may-june-polling-data https://phrma.org/resources/media-briefing-on-the-biopharmaceutical-supply-chain https://phrma.org/resources/medicines-in-development-for-infectious-diseases-2020-drug-list https://phrma.org/resources/memorandum-2020-election-data https://phrma.org/resources/memorandum-minnesota-voter-data https://phrma.org/resources/milliman-report-reducing-part-d-beneficiary-costs-through-point-of-sale-rebates https://phrma.org/resources/august-2021-polling-data https://phrma.org/resources/barriers-to-value-based-agreements-for-drugs https://phrma.org/resources/biopharmaceutical-company-communications-with-health-care-stakeholders https://phrma.org/resources/biopharmaceutical-digital-health-lexicon https://phrma.org/resources/biopharmaceutical-industry-efforts-to-fight-covid-19-lessons-learned-and-preparing-for-future-pandemics https://phrma.org/resources/biopharmaceutical-manufacturing-in-the-u-s https://phrma.org/resources/chart-pack-biopharmaceuticals-in-perspective-fall-2020 https://phrma.org/resources/chart-pack-biopharmaceuticals-in-perspective https://phrma.org/resources/chart-pack-rare-diseases-and-the-orphan-drug-act https://phrma.org/resources/copay-accumulators-and-maximizers-payer-management-approach https://phrma.org/resources/corporate-venture-capital-report https://phrma.org/resources/covid-19-vaccines-global-production-and-uptake https://phrma.org/resources/december-2021-polling-data https://phrma.org/resources/disparities-in-data-solutions-and-barriers-to-implementation https://phrma.org/resources/fall-health-care-priorities-for-consumers https://phrma.org/resources/follow-the-dollar-part-2 https://phrma.org/resources/gene-therapies-can-bring-hope-to-patients-with-blood-disorders https://phrma.org/resources/health-care-landscape-national-study-data https://phrma.org/resources/health-care-landscape-poll-californias-52nd-congressional-district https://phrma.org/resources/health-care-landscape-poll-new-jerseys-5th-congressional-district https://phrma.org/resources/health-care-landscape-poll https://phrma.org/resources/health-care-policy-should-get-us-closer-to-health-equity-the-inflation-reduction-act-fails-to-do-so https://phrma.org/resources/healthy-aging-the-role-of-innovative-medicines https://phrma.org/resources/implications-of-the-drug-pricing-provisions-in-reconciliation https://phrma.org/resources/industry-profile-2019 https://phrma.org/resources/january-2022-polling-data https://phrma.org/resources/medicines-in-development-for-neurological-disorders-2018-report https://phrma.org/resources/medicines-in-development-for-immuno-oncology-2017-report https://phrma.org/resources/bsufa-iii-phrma-priorities https://phrma.org/resources/deductibles-and-coinsurance-drive-high-out-of-pocket-costs-for-commercially-insured-patients-taking-brand-medicines https://phrma.org/resources/commercially-insured-patients-with-chronic-conditions-face-high-cost-sharing-for-brand-medicines https://phrma.org/resources/global-access-to-new-medicines-report https://phrma.org/resources/covered-by-insurance-but-still-exposed-barriers-to-care-for-insured-americans https://phrma.org/resources/eqbmed-2022-year-end-update https://phrma.org/resources/industry-profile-2022 https://phrma.org/resources/how-the-iras-drug-price-setting-program-threatens-seniors-access-to-medicines https://phrma.org/resources/faced-with-high-cost-sharing-for-brand-medicines-many-commercially-insured-patients-with-chronic-conditions-use-manufacturer-cost-sharing-assistance https://phrma.org/resources/data-shows-americans-reject-so-called-medicare-negotiation https://phrma.org/resources/colorado-prescription-medicine-affordability-poll-january-2022 https://phrma.org/resources/chart-pack-biopharmaceuticals-in-perspective-summer-2019 https://phrma.org/resources/commercially-insured-patients-pay-undiscounted-list-prices-for-one-in-five-brand-prescriptions-accounting-for-half-of-out-of-pocket-spending-brand-medicines https://phrma.org/resources/delivering-results-for-patients-the-value-of-value-based-contracts https://phrma.org/resources/ebola-the-biopharm-industry-committed-to-advancements https://phrma.org/resources/how-icer-s-flawed-budget-impact-threshold-can-harm-patient-access https://phrma.org/resources/industry-profile-2021 https://phrma.org/resources/medicare-part-d-pocket-card https://phrma.org/resources/milliman-report-on-impact-of-moving-medicines-from-part-b-to-part-d-july-2018 https://phrma.org/resources/dtc-annual-report https://phrma.org/resources/list-of-2017-immuno-oncology-medicines-in-development https://phrma.org/resources/list-of-2017-medicines-in-development-for-alzheimer-s https://phrma.org/resources/list-of-2017-medicines-in-development-for-mental-illness https://phrma.org/resources/list-of-2018-medicines-in-development-for-cancer https://phrma.org/resources/list-of-2018-medicines-in-development-for-skin-disease https://phrma.org/resources/list-of-2019-medicines-in-development-for-asthma https://phrma.org/resources/list-of-medicines-in-development-for-hiv-2017 https://phrma.org/resources/list-of-medicines-in-development-for-vaccines-2017 https://phrma.org/resources/medicines-in-development-for-alzheimer-s-disease https://phrma.org/resources/medicines-in-development-for-asthma-and-allergy-2019-report https://phrma.org/resources/medicines-in-development-for-autoimmune-disease-drug-list https://phrma.org/resources/medicines-in-development-for-cancer-2018-report https://phrma.org/resources/medicines-in-development-for-cancer-2020-report https://phrma.org/resources/medicines-in-development-for-cancer-2023-drug-list https://phrma.org/resources/medicines-in-development-for-cell-and-gene-therapy-2018-drug-list https://phrma.org/resources/medicines-in-development-for-cell-and-gene-therapy-2018-report https://phrma.org/resources/medicines-in-development-for-cell-and-gene-therapy-2020-drug-list https://phrma.org/resources/medicines-in-development-for-children-2012-report https://phrma.org/resources/medicines-in-development-for-children-2020-drug-list https://phrma.org/resources/medicines-in-development-for-chronic-illness-older-americans-2023-report https://phrma.org/resources/medicines-in-development-for-copd-2012-report https://phrma.org/resources/medicines-in-development-for-diabetes-2019-report https://phrma.org/resources/medicines-in-development-for-heart-disease-and-stroke-2018-drug-list https://phrma.org/resources/medicines-in-development-for-heart-disease-and-stroke-2018-report https://phrma.org/resources/medicines-in-development-for-hiv-2017-report https://phrma.org/resources/medicines-in-development-for-leukemia-and-lymphoma-2015-report https://phrma.org/resources/medicines-in-development-for-mental-illness-2019-drug-list https://phrma.org/resources/medicines-in-development-for-mental-illness-2019-report https://phrma.org/resources/medicines-in-development-for-mental-illness-2023-report https://phrma.org/resources/medicines-in-development-for-mental-illnesses-2017-report https://phrma.org/resources/medicines-in-development-for-neurodegenerative-diseases-2021-drug-list https://phrma.org/resources/medicines-in-development-for-neurological-disorders-2018-drug-list https://phrma.org/resources/medicines-in-development-for-parkinsons-disease-2014-report https://phrma.org/resources/medicines-in-development-for-sickle-cell-disease-2019-drug-list https://phrma.org/resources/medicines-in-development-for-sickle-cell-disease-2019-report https://phrma.org/resources/medicines-in-development-for-skin-diseases-2018-update https://phrma.org/resources/medicines-in-development-for-vaccines-2017-update https://phrma.org/resources/medicines-in-development-for-vaccines-2020-drug-list https://phrma.org/resources/medicines-in-development-for-women-2013-report https://phrma.org/resources/medicines-in-development-for-chronic-diseases-2024-report https://phrma.org/resources/medicines-in-development-for-vaccines-2024-report https://phrma.org/resources/medicines-in-development-for-cancer-2023-report https://phrma.org/resources/phrma-50-state-poll-fall-2021 https://phrma.org/resources/phrma-collaborative-actions-to-reach-equity-cares-grant-2023 https://phrma.org/resources/phrma-comments-in-the-who-pandemic-agreement https://phrma.org/resources/phrma-comments-on-need-for-timely-reauthorization-of-pandemic-and-all-hazards-preparedness-act https://phrma.org/resources/phrma-comments-on-part-one-of-the-medicare-prescription-payment-plan-draft-guidance-for-part-d https://phrma.org/resources/phrma-litigation-challenging-340b-administrative-dispute-resolution-final-rule https://phrma.org/resources/phrma-litigation-challenging-constitutionality-of-provisions-in-arkansas-act-1103 https://phrma.org/resources/phrma-litigation-challenging-final-rule-on-drug-importation-from-canada https://phrma.org/resources/phrma-litigation-challenging-legality-of-the-administrations-most-favored-nation-rule https://phrma.org/resources/phrma-litigation-challenging-the-medicaid-accumulator-rule https://phrma.org/resources/phrma-response-to-the-senate-request-for-information-on-the-340b-drug-pricing-program https://phrma.org/resources/phrma-special-301-submission-2024 https://phrma.org/resources/point-of-sale-rebate-analysis-in-the-commercial-market https://phrma.org/resources/premium-impacts-of-pos-rebate-implementation-in-the-aca-market-in-the-state-of-arkansas https://phrma.org/resources/progress-built-on-commitment-phrma-equity-in-2022 https://phrma.org/resources/role-of-bayh-doyle-in-fostering-innovation https://phrma.org/resources/september-2021-polling-data https://phrma.org/resources/tackling-impediments-to-trade https://phrma.org/resources/the-inflation-reduction-acts-price-setting-policies-do-more-harm-than-good-for-underserved-communities https://phrma.org/resources/the-pharmaceutical-supply-chain-and-impacts-of-advance-price-notification https://phrma.org/resources/the-us-vs-other-countries-availability-of-medicines-varies https://phrma.org/resources/trends-in-out-of-pocket-spending-for-brand-medicines-in-medicare-part-d https://phrma.org/resources/trends-in-profitability-and-compensation-of-pbms-and-pbm-contracting-entities https://phrma.org/resources/understanding-medicare-part-b-pocket-card https://phrma.org/resources/what-is-the-orange-book https://phrma.org/resources/milliman-study-on-limitations-in-using-icer-s-potential-budget-impact-work-to-guide-private-payer-budget-decisions https://phrma.org/resources/moran-company-study-on-hospital-charges-and-reimbursement-for-medicines https://phrma.org/resources/mrp-survey-results-50-state-poll https://phrma.org/resources/october-2021-polling-data https://phrma.org/resources/omi-battleground-survey-may-2022 https://phrma.org/resources/oregon-july-polling-data https://phrma.org/resources/overview-and-101-digital-health https://phrma.org/resources/patient-experience-survey-barriers-to-health-care-access-in-the-patient-experience https://phrma.org/resources/patient-experience-survey-data-document https://phrma.org/resources/patient-experience-survey-report https://phrma.org/resources/nearly-a-decade-of-treatment-advances-bring-cures-to-the-vast-majority-of-hepatitis-c-patients https://phrma.org/resources/prescription-medicines-costs-in-context https://phrma.org/resources/research-in-iowa https://phrma.org/resources/research-in-new-jersey https://phrma.org/resources/research-in-north-carolina https://phrma.org/resources/research-in-oregon https://phrma.org/resources/research-in-pennsylvania https://phrma.org/resources/research-in-washington https://phrma.org/resources/phrma-litigation-challenging-constitutionality-of-provisions-in-louisiana-act-358 https://phrma.org/resources/prescription-medicines-insulin-costs-in-context https://phrma.org/resources/prescription-medicine-insulin-costs-in-context-en-espanol https://phrma.org/resources/more-than-half-of-every-dollar-spent-on-medicines-goes-to-someone-who-doesnt-make-them https://phrma.org/resources/morning-consult-pbm-poll-may-2024 https://phrma.org/resources/morning-consult-national-tracking-poll-july-2022 https://phrma.org/resources/morning-consult-national-tracking-poll-august-2022 https://phrma.org/resources/prescription-medicines-international-costs-in-context https://phrma.org/resources/phrma-collaborative-actions-to-reach-equity-cares-grant-2024 https://phrma.org/resources/phrmas-comments-to-us-food-and-drug-administrations-draft-guidance-on-decentralized-clinical-trials-for-drugs-biological-products-and-devices https://phrma.org/resources/september-2024-registered-voter-survey-results https://phrma.org/resources/the-biopharmaceutical-industrys-sustained-commitment-to-inspiring-and-advancing-tomorrows-stem-workforce https://phrma.org/resources/nica-gcca-phrma-litigation-asserts-price-setting-provisions-in-the-inflation-reduction-act-are-unconstitutional https://phrma.org/resources/new-50-state-poll-shows-perils-of-so-called-medicare-negotiation https://phrma.org/resources/recent-polling-on-medicare-negotiation-misleads-independent-non-partisan-polling-actually-shows-voter-support-evaporating https://phrma.org/resources/national-health-expenditures-2018-data-release https://phrma.org/resources/using-icer-s-value-assessments-would-limit-access-to-life-saving-medicines-in-medicare-part-b https://phrma.org/resources/revisiting-the-pharmaceutical-supply-chain-2013-2018 https://phrma.org/resources/women-girls-and-stem https://phrma.org/resources/phrma-comments-on-advancing-inclusive-worker-centered-trade-policy https://phrma.org/resources/an-open-letter-from-americas-biopharmaceutical-companies https://phrma.org/resources/letter-to-florida-governor-ron-desantis-on-hb-19 https://phrma.org/resources/letter-to-president-biden-from-31-phrma-board-members https://phrma.org/resources/phrma-ceos-express-grave-concern-with-the-inflation-reduction-act-of-2022 https://phrma.org/resources/phrma-comments-to-the-department-of-commerce-on-negotiating-objectives-for-indo-pacific-economic-framework-ipef https://phrma.org/resources/phrma-comments-to-the-office-of-science-and-technology-policy-regarding-clinical-research-infrastructure-and-emergency-clinical-trials https://phrma.org/resources/phrma-comments-to-ustr-on-negotiating-objectives-for-indo-pacific-economic-framework-ipef https://phrma.org/resources/phrma-comment-letter-to-nist-on-the-bayh-dole-act https://phrma.org/resources/phrma-comment-on-oig-regulatory-sprint-proposed-rule https://phrma.org/resources/phrma-comment-on-the-health-care-innovation-caucus-request-for-information https://phrma.org/resources/phrma-comments-on-cms-proposed-rule-on-changes-to-medicaid https://phrma.org/resources/phrma-comments-on-inflation-reduction-act-price-setting-guidance https://phrma.org/resources/phrma-comments-on-medicaid-drug-rebate-program-proposed-rule https://phrma.org/resources/phrma-comments-on-medicare-prescription-payment-plan-draft-part-two-guidance https://phrma.org/resources/phrma-comments-on-promoting-supply-chain-resilience https://phrma.org/resources/phrma-comments-on-section-1557-nondiscrimination-proposed-rule https://phrma.org/resources/phrma-comments-on-the-florida-agency-on-health-care-administration-s-request-for-information-on-importation https://phrma.org/resources/phrma-comments-on-the-national-strategy-for-expanding-american-innovation https://phrma.org/resources/phrma-comments-to-usitc-on-covid-19-diagnostics-and-therapeutics-supply-demand-and-trips-agreement-flexibilities https://phrma.org/resources/phrma-comments-in-response-to-2019-hospital-outpatient-prospective-payment-system-proposed-rule https://phrma.org/resources/phrma-comments-to-ftc-on-the-impact-of-pharmacy-benefit-managers-business-practices https://phrma.org/resources/2025-national-trade-estimate-report-on-foreign-trade-barriers-nte https://phrma.org/resources/phrma-comments-on-administrations-proposed-rule-on-drug-importation https://phrma.org/resources/phrma-comments-to-nists-rfi-draft-march-in-rights https://phrma.org/resources/phrma-comments-to-usitc-on-distributional-effects-of-trade-and-trade-policy-on-us-workers https://phrma.org/resources/phrma-comments-to-cms-on-proposed-national-coverage-determination-for-monoclonal-antibodies-for-the-treatment-of-alzheimers-disease https://phrma.org/resources/phrma-comments-to-cms-on-plan-to-amend-tennessees-section-1115-demonstration https://phrma.org/resources/phrma-2024-comments-to-the-nih-office-of-science-policy-draft-nih-intramural-research-program-policy https://phrma.org/resources/part-d-comment-letter-february-2021 https://phrma.org/resources/part-d-comment-letter-april-2020 https://phrma.org/resources/phrma-comment-letter-on-cms-proposed-rule-january-2021 https://phrma.org/resources/phrma-comment-letter-on-cms-proposed-rule-march-2020 https://phrma.org/resources/the-prescription-drug-user-fee-act-vii https://phrma.org/resources/research-in-wisconsin https://phrma.org/resources/navigating-the-patient-experience-the-barriers-and-burdens-standing-between-patients-and-care https://phrma.org/resources/slides https://phrma.org/resources/small-molecule-medicines-why-theyre-vital-for-patients https://phrma.org/resources/phrma-testimony-on-fda-user-fee-reauthorization https://phrma.org/resources/milken-institute-future-of-health-summit https://phrma.org/resources/chart-pack-medicines-in-medicare-part-d https://phrma.org/resources/chart-pack-medicines-in-medicaid https://phrma.org/resources/chart-pack-medicines-in-veterans-affairs https://phrma.org/resources/building-a-better-health-care-system-summary https://phrma.org/resources/the-biopharmaceutical-research-ecosystem-five-things-you-need-to-know https://phrma.org/resources/advancing-biopharmaceutical-innovation-in-diabetes https://phrma.org/resources/infographic-value-assessment-should-include-all-aspects-of-value-that-matter-to-patients https://phrma.org/resources/inflation-reduction-act-already-impacting-r-and-d https://phrma.org/resources/follow-the-dollar-executive-summary https://phrma.org/resources/340b-drug-discount-program-pocket-card https://phrma.org/resources/chart-pack-medicines-in-medicare-part-b https://phrma.org/resources/the-bayh-dole-act-spurring-american-biopharmaceutical-innovation https://phrma.org/resources/the-us-biosimilars-market-continues-to-increase-competition-and-savings-but-reforms-are-needed-to-realize-its-full-potential https://phrma.org/resources/harms-of-trips-waiver-expansion https://phrma.org/resources/40-years-of-cancer-immunotherapy-research https://phrma.org/resources/policies-to-help-patients-pay-less-for-their-medicines-share-the-savings https://phrma.org/resources/policies-to-help-patients-pay-less-for-their-medicines-offer-lower-more-predictable-cost-sharing-options https://phrma.org/resources/policies-to-help-patients-pay-less-for-their-medicines-cover-medicines-from-day-one https://phrma.org/resources/policies-to-help-patients-pay-less-for-their-medicines-cap-patient-cost-sharing https://phrma.org/resources/hold-pharmacy-benefit-managers-accountable-under-state-law https://phrma.org/resources/the-prescription-drug-user-fee-act-fact-sheet https://phrma.org/resources/understanding-medicine-abandonment-as-a-barrier-to-health-equity https://phrma.org/resources/access-denied-patients-speak-out-on-health-insurance-barriers-and-the-need-for-policy-change https://phrma.org/resources/how-the-biopharmaceutical-industry-has-responded-to-covid-19 https://phrma.org/resources/understanding-the-emergency-use-authorization-process-for-covid-19-vaccines https://phrma.org/resources/building-a-better-health-care-system-phrmas-patient-centered-agenda https://phrma.org/resources/statement-on-revisions-to-the-phrma-code-on-interactions-with-health-care-professionals https://phrma.org/resources/gaps-in-available-data-exacerbate-health-disparities-and-create-barriers-to-change https://phrma.org/resources/endpoints-at-jpm25-healthcare-policy-under-the-new-administration https://phrma.org/resources/fierce-jpm-week https://phrma.org/resources/addressing-disparities-in-medication-access-and-adherence https://phrma.org/resources/wtops-the-health-care-agenda-2024-real-policies-for-real-people https://phrma.org/resources/analysis-of-quarterly-changes-in-average-sales-price-of-part-b-medicines-from-q1-to-q2-2022 https://phrma.org/resources/fact-sheet-on-challenges-with-amr https://phrma.org/resources/patient-experience https://phrma.org/resources/working-together-to-fight-covid-19-vaccine-manufacturing-collaborations https://phrma.org/resources/setting-up-a-pharmaceutical-manufacturing-process-and-supply-chain-a-complex-lengthy-undertaking https://phrma.org/resources/policies-to-help-patients-pay-less-for-their-medicines-make-insurance-work https://phrma.org/resources/building-a-better-health-care-system-print-ad https://phrma.org/resources/development-of-new-medicines-relies-on-private-sector-expertise-and-investment https://phrma.org/resources/amr-ecosystem https://phrma.org/resources/pdufa-driving-efficiencies-in-the-drug-review-process https://phrma.org/resources/biopharma-as-a-strategic-asset-insights https://phrma.org/resources/industry-collaboration-and-partnerships-are-supporting-covid-19-vaccine-manufacturing https://phrma.org/resources/americas-biopharmaceutical-industry-is-central-to-a-diverse-randd-ecosystem https://phrma.org/resources/barriers-to-results-based-contracts https://phrma.org/resources/worried-about-affording-your-medicine-mat-is-here-to-help https://phrma.org/resources/share-the-savings-hospitals https://phrma.org/resources/the-unique-r-and-d-ecosystem-delivering-new-treatments-and-cures-to-patients https://phrma.org/resources/follow-the-dollar-insulin-patients-in-high-deductible-health-plans https://phrma.org/resources/whats-the-deal-with-these-prescription-drug-middlemen https://phrma.org/resources/together-type-2-diabetes https://phrma.org/resources/together-migraine https://phrma.org/resources/together-car-t https://phrma.org/resources/together-asthma https://phrma.org/resources/strong-ip-protections-lead-to-stronger-treatments-for-all https://phrma.org/resources/spending-on-medicines-the-big-picture https://phrma.org/resources/phrma-submission-to-the-world-health-organization-on-international-pandemic-preparedness https://phrma.org/resources/phrma-submission-to-pandemic-fund-g20-pledging-event https://phrma.org/resources/innovation-spotlight-collaboration-fueling-biopharmaceutical-advancements https://phrma.org/resources/how-does-health-insurance-cover-your-medicines https://phrma.org/resources/health-insurance-coverage-101 https://phrma.org/resources/health-coverage-hurdles https://phrma.org/resources/follow-the-dollar https://phrma.org/resources/drug-discovery https://phrma.org/resources/clinical-trials-what-you-need-to-know https://phrma.org/resources/a-new-era-in-cancer-innovation https://phrma.org/resources/innovation-spotlight-battling-cancer-together-phrma-octobe https://phrma.org/resources/ubl-pbs-newshour-segment-external-content-promo https://phrma.org/resources/phrma-oral-hearing-statement-to-usitc-on-covid-19-diagnostics-and-therapeutics-supply-demand-and-trips-agreement-flexibilities https://phrma.org/resources/clinical-trial-data-sharing-fact-sheet https://phrma.org/resources/phrma-awards-nearly-500k-to-community-based-projects-to-address-inequities-in-diagnosis-treatment-and-adherence https://phrma.org/resources/phrma-statement-on-rfk-hhs-nomination https://phrma.org/resources/phrma-statement-on-the-2024-us-election https://phrma.org/resources/phrma-statement-on-president-bidens-address-to-joint-session-of-congress https://phrma.org/resources/phrma-congratulates-president-donald-trump-on-his-inauguration https://phrma.org/resources/phrma-statement-on-biopharmaceutical-companies-pledge-on-covid-19-vaccines https://phrma.org/resources/phrma-comments-ustr-on-the-us-eu-trade-and-technology-council-global-trade-challenges-working-group https://phrma.org/resources/phrma-international-pricing-index-model-comments https://phrma.org/resources/phrma-petition-to-hhs-for-rulemaking-regarding-an-administrative-dispute-resolution-process-for-the-340b-drug-pricing-program https://phrma.org/resources/phrma-response-to-request-for-input-on-modernizing-the-340b-drug-pricing-program https://phrma.org/resources/phrma-submission-to-the-uspto-on-initiatives-to-ensure-the-robustness-and-reliability-of-patent-rights https://phrma.org/resources/phrma-submission-to-the-uspto-on-joint-uspto-fda-collaboration-initiatives https://phrma.org/resources/phrma-final-written-submission-to-usitc-on-covid-19-diagnostics-and-therapeutics-supply-demand-and-trips-agreement-flexibilities https://phrma.org/resources/medicare-program-request-for-information-on-medicare https://phrma.org/resources/comments-on-congressional-social-determinants-of-health-caucus-request-for-information https://phrma.org/resources/comments-to-omb-on-methods-and-leading-practices-for-advancing-equity-for-underserved-communities-through-government https://phrma.org/resources/comments-on-cms-request-for-information-on-closing-the-health-equity-gap-in-cms-quality-programs https://phrma.org/resources/phrma-comments-to-nih-request-for-information-on-advancing-and-strengthening-racial-equity-in-the-biomedical-research-workforce https://phrma.org/resources/phrma-cures-2-0-call-to-action-comments https://phrma.org/resources/2022-industry-profile-toolkit-addressing-a-growing-public-health-emergency-antimicrobial-resistance https://phrma.org/resources/entities-that-don-t-make-medicines-get-half-of-what-is-spent-on-those-medicines https://phrma.org/resources/prea-and-bpca-spurring-pediatric-drug-development https://phrma.org/resources/follow-the-dollar-report-2025 https://phrma.org/resources/americas-biopharmaceutical-companies-continue-to-expand-advanced-manufacturing-across-the-united-states https://phrma.org/resources/phrma-special-301-submission-2025 https://phrma.org/resources/ipay-2027-list-underscores-urgent-need-to-fix-the-pill-penalty https://phrma.org/resources/phrma-comments-to-cms-on-contract-year-2026-medicare-advantage-and-part-d-proposed-rule https://phrma.org/resources/rare-disease-medicines-in-development https://phrma.org/resources/doj-and-ftc-listening-session-on-lowering-americans-drug-prices-through-competition-remarks https://phrma.org/resources/mounting-pressure-on-pbms-scrutiny-from-every-corner https://phrma.org/resources/pbms-and-commercial-insurers-are-blocking-prescription-access https://phrma.org/resources/thanks-to-americas-ip-system-medicine-costs-go-down-over-time https://phrma.org/resources/americas-ip-system-balances-innovation-and-affordability-but-middlemen-in-the-pharmaceutical-supply-chain-harm-access https://phrma.org/resources/phrma-statement-on-today-s-white-house-announcement https://phrma.org/resources/phrma-statement-on-hhs-confirmation https://phrma.org/resources/phrma-statement-on-the-make-our-children-healthy-again-strategy https://phrma.org/resources/phrma-statement-on-acip-meeting https://phrma.org/resources/kyowa-kirin-joins-phrma-strengthening-industry-presence-in-d-c https://phrma.org/resources/phrma-statement-on-autism https://phrma.org/resources/phrma-announces-major-actions-as-part-of-industry-s-commitment-to-american-patients-and-workers https://phrma.org/resources/test-comment https://phrma.org/resources/government-price-setting-policies-hurt-patients https://phrma.org/resources/the-facts-about-mental-health-medications https://phrma.org/resources/the-340b-hospital-markup-program-is-costing-taxpayers-employers-billions https://phrma.org/resources/medicare-enrollment-options-help-might-be-available https://phrma.org/resources/phrma-comments-on-application-process-for-the-340b-rebate-model-pilot-program https://phrma.org/resources/2026-national-trade-estimate-report-on-foreign-trade-barriers-submission https://phrma.org/resources/the-prescription-drug-user-fee-act https://phrma.org/resources/pharmacy-benefit-manager-reform-act https://phrma.org/resources/340b-access-act-a-major-step-to-prevent-medicine-markups https://phrma.org/resources/what-you-need-to-know-about-vaccine-ingredients https://phrma.org/resources/the-advancements-and-innovations-in-combatting-hiv-aids https://phrma.org/resources/phrma-statement-on-changes-to-the-childhood-vaccine-schedule https://phrma.org/resources/phrma-statement-on-the-white-house-s-great-healthcare-plan-announcement https://phrma.org/resources/phrma-welcomes-stemline-therapeutics-as-newest-member https://phrma.org/resources/phrma-responds-to-congressional-hearings-with-health-insurance-ceos https://phrma.org/resources/phrma-statement-on-ipay-2028-selected-drug-list https://phrma.org/resources/bipartisan-pbm-reforms-signed-into-law-advancing-transparency-and-lowering-costs-for-patients https://phrma.org/resources/phrma-statement-on-compounding-concerns https://phrma.org/resources/phrma-statement-on-ftc-settlement-with-express-scripts https://phrma.org/resources/phrma-launches-campaign-highlighting-the-importance-of-america-s-global-leadership-in-medicine-development https://phrma.org/resources/access-denied-patients-speak-out-on-insurance-barriers-and-the-need-for-policy-change https://phrma.org/resources/merck-s-robert-davis-becomes-new-chair-of-phrma-board https://phrma.org/resources/phrma-statement-on-president-trump-s-state-of-the-union-address https://phrma.org/resources/medicines-in-development-for-leading-chronic-diseases-affecting-older-americans-2023 https://phrma.org/resources/high-income-country-spending-on-innovative-medicines https://phrma.org/resources/340b-rebate-model-a-shield-against-program-abuse-and-rising-costs https://phrma.org/resources/340b-health-survey-misleads-ignores-the-problem-rebate-models-are-designed-to-solve https://phrma.org/resources/rebate-model-addressing-long-term-fraud-and-abuse-in-the-340b-program https://phrma.org/resources/340b-rebate-model-accountability-over-alarmism https://phrma.org/resources/phrma-statement-on-cms-guard-and-globe-proposed-rules https://phrma.org/resources/phrma-president-ceo-steve-ubl-announces-plans-for-leadership-transition https://phrma.org/resources/american-preparedness-for-the-annual-flu-season-relies-on-a-coordinated-national-strategy https://phrma.org/resources/phrma-statement-on-section-232-tariff-announcement https://phrma.org/resources/faq-340b-rebate-based-rapid-verification-model https://phrma.org/resources/seniors-face-growing-barriers-to-medicines-in-medicare-part-d https://phrma.org/resources/americas-leadership-is-at-risk https://phrma.org/resources/high-income-country-spending-on-innovative-medicine https://phrma.org/resources/phrmas-comments-on-cms-mfn-medicare-proposals-globe-and-guard https://phrma.org/resources/innovation-at-risk-americans-speak-out-on-u-s-pharmaceutical-leadership-and-the-need-for-affordable-access https://phrma.org/resources/phrma-2026-special-301-hearing-statement https://phrma.org/resources/changes-to-america-s-childhood-vaccine-schedule-fail-to-protect-our-nation-s-kids https://phrma.org/resources/340b-rebate-model-pilot-wouldnt-have-hurt-cash-flow-for-providers https://phrma.org/resources/phrma-special-301-submission-2026 https://phrma.org/resources/hospital-mark-ups-hurt-patients-according-to-new-50-state-poll https://phrma.org/resources/the-importance-of-the-biosimilar-user-fee-act-in-bringing-new-options-to-patients-and-increasing-competition https://phrma.org/resources/the-prescription-drug-user-fee-act-ensuring-the-timely-availability-of-safe-and-effective-medicines-for-patients https://phrma.org/resources/phrma-statement-on-december-acip-meeting https://phrma.org/resources/phrma-statement-on-cms-releasing-ipay-2027-mfps https://phrma.org/resources/phrma-comments-regarding-the-2026-joint-review-of-the-usmca https://phrma.org/resources/phrma-comments-on-cms-proposed-rule-cy-2026 https://phrma.org/resources/phrma-submits-post-hearing-comments-in-brazil-section-301-investigation https://phrma.org/resources/phrma-comments-on-section-301-investigation-of-acts-policies-and-practices-of-brazil https://phrma.org/resources/persistent-growth-in-pbm-formulary-exclusions-continues-to-raise-concerns-about-patient-access https://phrma.org/resources/2025-phrma-annual-membership-survey https://phrma.org/resources/340b-the-hospital-markup-program https://phrma.org/resources/stat-phrma-ceo-most-favored-nation-policy-isn-t-the-way-to-lower-drug-prices https://phrma.org/resources/phrma-comments-on-draft-guidance-of-medicare-drug-price-negotiation-program https://phrma.org/resources/phrma-comments-on-foreign-nations-freeloading-on-american-financed-innovation https://phrma.org/resources/phrma-statement-on-this-weeks-acip-meetings https://phrma.org/resources/medicare-part-d-plans-and-pbms-initially-denied-more-than-70-of-patients-their-prescribed-medicines-for-four-chronic-conditions https://phrma.org/resources/phrma-statement-on-the-maha-commission-report https://phrma.org/resources/foreign-reference-pricing-is-bad-for-americans https://phrma.org/resources/growing-momentum-to-address-the-340b-hospital-markup-program https://phrma.org/resources/phrma-statement-on-most-favored-nation-executive-order https://phrma.org/resources/strong-us-trade-policy-fuels-american-leadership-in-biopharmaceutical-innovation-and-manufacturing https://phrma.org/resources/phrma-comments-to-us-department-of-commerce-on-232-investigation https://phrma.org/resources/how-intellectual-property-drives-us-innovation-and-biopharmas-impact https://phrma.org/resources/phrma-welcomes-astrazeneca-to-the-association https://phrma.org/resources/phrmas-comments-to-the-food-and-drug-administration-on-the-considerations-for-the-use-of-artificial-intelligence-to-support-regulatory-decision-making-for-drug-and-biological-products https://phrma.org/resources/3-myths-critics-get-wrong-about-intellectual-property https://phrma.org/resources/its-time-to-protect-patients-and-fix-the-pill-penalty https://phrma.org/resources/phrma-members-have-produced-vaccines-across-the-united-states https://phrma.org/resources/phrmas-comments-to-the-office-of-science-and-technology-policy-networking-and-information-technology-research-and-development-national-coordination-offices-request-for-information-on-the-development-of-an-artificial-intelligence-action-plan https://phrma.org/resources/artificial-intelligence-and-biopharmaceutical-innovation https://phrma.org/resources/inappropriate-pbm-and-insurance-utilization-management-practices-can-impede-patient-access-to-quality-care https://phrma.org/resources/phrma-comments-on-unfair-and-non-reciprocal-trade-practices https://phrma.org/resources/health-care-practitioner-and-patient-experiences-inappropriate-pbm-and-insurance-utilization-management-practices-can-impede-patient-access-to-quality-care https://phrma.org/resources/strong-us-trade-policy-fuels-american-biopharmaceutical-innovation https://phrma.org/resources/phrma-2025-special-301-hearing-statement https://phrma.org/resources/dr-albert-bourla-of-pfizer-becomes-new-chair-of-phrma-board https://phrma.org/resources/2025-policy-agenda-solutions-for-a-healthier-america https://phrma.org/resources/phrma-releases-new-innovation-report-and-2025-policy-agenda-for-achieving-a-healthier-america https://phrma.org/resources/report-the-pharmaceutical-supply-chain-2013-2023 https://phrma.org/resources/future-of-medicine-cell-gene-therapies https://phrma.org/resources/the-national-vaccine-injury-compensation-program https://phrma.org/resources/fact-sheet-patient-experience-survey-protecting-lifelines-to-access-and-innovation https://phrma.org/resources/fact-sheet-patient-experience-survey-navigating-the-patient-experience-the-barriers-and-burdens-standing-between-patients-and-care https://phrma.org/resources/fact-sheet-patient-experience-survey-barriers-to-health-care-access-in-the-patient-experience https://phrma.org/resources/debunking-false-narratives-about-the-patent-system-biopharmaceutical-companies-extend-market-exclusivity-through-so-called-evergreening-practices https://phrma.org/resources/debunking-false-narratives-about-the-patent-system-biopharmaceutical-patent-thickets https://phrma.org/resources/hatch-waxman-america-s-pathway-for-low-cost-generics-and-incentives-for-innovation https://phrma.org/resources/phrma-statement-on-ustr-s-initiation-of-section-301-investigation-against-germany https://phrma.org/resources/compounded-drugs-how-they-differ-from-fda-approved-medicines https://phrma.org/resources/the-workforce-skilling-investments-behind-the-biopharmaceutical-industry-s-u-s-manufacturing-expansion https://phrma.org/resources/lessons-learned-the-biopharmaceutical-industry-s-response-to-covid-19 https://phrma.org/resources/what-you-need-to-know-peptides-and-compounding https://phrma.org/resources/access-to-new-medicines-in-the-united-states-vs-other-high-income-countries https://phrma.org/resources/protecting-progress-against-hib-with-continued-vaccination-and-monitoring https://phrma.org/resources/price-setting-is-the-wrong-approach-for-americans-lessons-learned-from-the-ira https://phrma.org/resources/request-for-information-340b-rebate-model-pilot-program https://phrma.org/resources/prepared-remarks-of-david-korn-ptab-listening-session https://phrma.org/resources/vaccines-a-high-return-investment-for-americas-health-and-our-nations-economy https://phrma.org/resources/the-patent-thicket-talking-point-falls-apart-under-scrutiny https://phrma.org/resources/new-business-model-optional-same-profit-driven-middlemen-guaranteed https://phrma.org/resources/phrma-submission-on-germany-s-persistent-underpayment-for-innovative-pharmaceutical-products https://phrma.org/resources/high-income-countries-under-spend-on-innovative-medicines https://phrma.org/resources/phrma-statement-on-childhood-vaccine-schedule-executive-order https://phrma.org/resources/innovation-in-the-biopharmaceutical-pipeline https://phrma.org/resources/phrma-statement-on-the-prescription-drug-user-fee-act-pdufa-viii-performance-goals-letter https://phrma.org/resources/about-phrma https://phrma.org/resources/phrma-comments-on-medicare-drug-price-negotiation-program-and-medicare-prescription-drug-benefit-program-proposed-rule-cms-4215-p https://phrma.org/resources/rfi-to-senate-finance-committee-commonsense-policy-options-to-lower-drug-prices-for-patients https://phrma.org/resources/340b-big-tax-exempt-hospitals-are-pocketing-billions-by-exploiting-a-federal-safety-net-program-at-the-expense-of-taxpayers https://phrma.org/resources/every-patent-stands-alone-debunking-the-evergreening-myth https://phrma.org/resources/better-medicines-not-meaningless-tweaks-debunking-the-product-hopping-myth https://phrma.org/resources/certification-submission https://phrma.org/resources/state-map/clinical-trials https://phrma.org/resources/state-map/stem https://phrma.org/resources/state-map/economic-impact https://phrma.org/resources/state-map/alaska https://phrma.org/resources/state-map/arkansas https://phrma.org/resources/state-map/arizona https://phrma.org/resources/state-map/district-of-columbia https://phrma.org/resources/state-map/delaware https://phrma.org/resources/state-map/connecticut https://phrma.org/resources/state-map/colorado https://phrma.org/resources/state-map/california https://phrma.org/resources/state-map/idaho https://phrma.org/resources/state-map/hawaii https://phrma.org/resources/state-map/georgia https://phrma.org/resources/state-map/maine https://phrma.org/resources/state-map/louisiana https://phrma.org/resources/state-map/kentucky https://phrma.org/resources/state-map/kansas https://phrma.org/resources/state-map/iowa https://phrma.org/resources/state-map/new-mexico https://phrma.org/resources/state-map/north-dakota https://phrma.org/resources/state-map/north-carolina https://phrma.org/resources/state-map/new-jersey https://phrma.org/resources/state-map/new-york https://phrma.org/resources/state-map/oklahoma https://phrma.org/resources/state-map/ohio https://phrma.org/resources/state-map/oregon https://phrma.org/resources/state-map/puerto-rico https://phrma.org/resources/state-map/pennsylvania https://phrma.org/resources/state-map/indiana https://phrma.org/resources/state-map/illinois https://phrma.org/resources/state-map/montana https://phrma.org/resources/state-map/missouri https://phrma.org/resources/state-map/mississippi https://phrma.org/resources/state-map/minnesota https://phrma.org/resources/state-map/michigan https://phrma.org/resources/state-map/massachusetts https://phrma.org/resources/state-map/maryland https://phrma.org/resources/state-map/new-hampshire https://phrma.org/resources/state-map/nevada https://phrma.org/resources/state-map/nebraska https://phrma.org/resources/state-map/wyoming https://phrma.org/resources/state-map/wisconsin https://phrma.org/resources/state-map/west-virginia https://phrma.org/resources/state-map/washington https://phrma.org/resources/state-map/virginia https://phrma.org/resources/state-map/vermont https://phrma.org/resources/state-map/utah https://phrma.org/resources/state-map/texas https://phrma.org/resources/state-map/tennessee https://phrma.org/resources/state-map/south-dakota https://phrma.org/resources/state-map/south-carolina https://phrma.org/resources/state-map/rhode-island https://phrma.org/resources/state-map/florida https://phrma.org/resources/state-map/alabama https://phrma.org/resources/state-map/programs-and-initiatives https://phrma.org/resources/state-map/340b https://phrma.org/our-agenda https://phrma.org/importation https://phrma.org/states https://phrma.org/vaccines-resources https://phrma.org/moonshot https://phrma.org/privacy-policy https://phrma.org/media-contacts https://phrma.org/terms-of-service https://phrma.org/newsroom https://phrma.org/events https://phrma.org/sitemap https://phrma.org/search https://phrma.org/unsubscribe https://phrma.org/eqbmed https://phrma.org/newsletter https://phrma.org/preference-center https://phrma.org/membership https://phrma.org/patient-experience-survey